Panacea Biotec Ltd (PANACEABIO)
₹313.25
Mkt cap
₹1,919 Cr
P/E ratio
—
P/B
2.30
Div yield
0.00%
ROE
−2.42%
ROCE
−2.43%
EPS (TTM)
—
Book value
₹136
52W range
292–647
Sector
Healthcare
Price history
Previous close
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company [1]
NSE PANACEABIOBSE 531349
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsBearish
52-week range
−51.58% from high₹313
₹292+7.13% from low₹647
Current
₹313.25
Prev close
₹325.90
Day
−3.88%
Price performance
1D
−4.54%
1W
−0.11%
1M
−17.10%
3M
−24.94%
6M
−16.09%
1Y
−29.26%
YTD
−17.53%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 | 141.13 | 165.19 | 166.75 | 199.57 | |
| Expenses | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 | 167.88 | 158.92 | 153.45 | 164.18 | 193.90 | |
| Operating Profit | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 | -1.18 | -17.79 | 11.74 | 2.57 | 5.67 | |
| OPM % | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% | -0.71% | -12.61% | 7.11% | 1.54% | 2.84% | |
| Other Income | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 | 16.99 | 9.10 | 5.05 | 5.26 | 6.98 | |
| Interest | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 | 0.86 | 2.14 | 1.85 | 1.20 | 1.18 | |
| Depreciation | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 | 8.39 | 8.34 | 8.45 | 7.88 | 7.90 | |
| Profit before tax | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 | -19.17 | 6.49 | -1.25 | 3.57 | |
| Tax % | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% | 39.63% | -26.92% | 40.06% | -20.00% | 38.38% | |
| Net Profit | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 | -14.01 | 3.89 | -1.00 | 2.20 | |
| EPS in Rs | 1.79 | -1.35 | -0.37 | -0.32 | -2.58 | 0.78 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 | 0.38 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202672.48%Promoter
Promoters72.48%
FIIs2.75%0.44
DIIs2.47%0.22
Public22.31%0.65
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Panacea Biotec | ₹313.25 | — | 1,919 | 0.00% | 2 | +113.06% | 200 | +19.72% | −2.43% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts2
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Oct - Please find attached newspaper copies regarding notice intimating the investors about the opening of special window for transfer and dematerialisation of physical sharesCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - Please find attached certificate dated October 01, 2026 issued by Skyline Financial Services Pvt. Ltd. ("RTA") confirming compliance under Regulation 74(5) of the SEBI (Depositories …Details Of Shares Dematerialized During September 2026
Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018 7 Oct - Panacea Biotec reported September 2026 dematerialization of 1,000 shares; total demat shares reached 6,11,09,526.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 1 Oct - 42nd AGM voting results: all 5 resolutions passed on September 29, 2026.Shareholder Meeting / Postal Ballot-Outcome of AGM 1 Oct